Jump to content
VA Disability Community via Hadit.com

Ask Your VA   Claims Questions | Read Current Posts 
Read Disability Claims Articles
 Search | View All Forums | Donate | Blogs | New Users | Rules 

  • homepage-banner-2024-2.png

  • donate-be-a-hero.png

Fda Finds Fault With Generic Toprol Xl

Rate this topic


Recommended Posts

Some of you may know about this, but this information is very important. This is probably the most prescribed beta blocker on the market. I would contact my prescribing doctor immediately if you take this generic form - Metoprolol Succinate ER.

========================================================

Latest News: FDA Finds Fault with Generic Toprol XL -- Problems Reported Earlier by ConsumerLab.com

(Date Posted: 8/28/2008)

On August 12, 2008, the U.S. FDA sent a letter to Sandoz Inc. warning of violations in its manufacture of Metoprolol Succinate ER tablets and other drug products. Sandoz's Metoprolol Succinate ER tablets are generic versions of Toprol XL.

In March 2008, ConsumerLab.com reported on consumer complaints with Sandoz's Metoprolol Succinate ER. As described in the ConsumerLab.com report, consumers have experienced increased blood pressure, increased heart rate and ectopic beats, as well as side effects such as nausea, dizziness and headaches when switched from Toprol XL to Metoprolol Succinate ER. ConsumerLab.com noted that the Sandoz formulation of the product is different from Toprol XL and dissolves in a different manner.

In its letter to Sandoz, the FDA states that, based on an inspection of a North Carolina plant in March 2008, Sandoz failed to appropriately validate the manufacturing process for Metoprolol Succinate (25 and 50 mg). Some lots were found to fail tests for content uniformity or dissolution. The FDA noted that Sandoz's practices represented a "moving target of quality."

The FDA notes that Sandoz did not conduct timely investigations of lots that failed dissolution testing. In addition, Sandoz chose to continue to release product even after being notified of violations.

The FDA concluded that Sandoz does "not provide a high level of assurance" that its process is "capable of producing a product that meets specifications." The FDA added, "We question the continued distribution of this product until better process controls are implemented and process validation is completed." The FDA requires that Sandoz take prompt action to correct the violations.

http://www.consumerlab.com/recalls.asp

http://www.fda.gov/foi/warning_letters/s6891c.pdf

Link to comment
Share on other sites

  • Replies 1
  • Created
  • Last Reply

Top Posters In This Topic

Popular Days

Top Posters In This Topic

Create an account or sign in to comment

You need to be a member in order to leave a comment

Create an account

Sign up for a new account in our community. It's easy!

Register a new account

Sign in

Already have an account? Sign in here.

Sign In Now
×
×
  • Create New...

Important Information

Guidelines and Terms of Use